Akari Therapeutics (AKTX) Amortization - Intangibles (2015)

Akari Therapeutics (AKTX) posted quarterly Amortization - Intangibles of $19.3 million for Q3 2015.

Akari Therapeutics (AKTX) Amortization - Intangibles (2015) Analysis & Trends

Akari Therapeutics (AKTX) has reported Amortization - Intangibles for 1 consecutive years, with $19.3 million the latest figure, recorded in Q3 2015.

  • Quarterly Amortization - Intangibles changed N/A year-over-year to $19.3 million in Q3 2015, while the trailing twelve-month figure through Dec 2015 was $19.3 million (changed N/A YoY) and the FY2015 annual result came in at $19.3 million, changed N/A from the prior year.
  • Amortization - Intangibles was little changed at $19.3 million in Q3 2015 per AKTX's latest filing.
  • Over the last five years, Amortization - Intangibles for AKTX reached as high as $19.3 million in Q3 2015 and fell as low as $19.3 million in Q3 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Akari Therapeutics 86.55 Mn 86.55 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2015 19.28 Mn